New hope for brain cancer: experimental drug MT-125 enters early trials

NCT ID NCT07604285

First seen Jun 01, 2026 · Last updated Jun 13, 2026 · Updated 2 times

Summary

This early-phase study tests a new drug called MT-125 given alongside standard chemoradiation for people newly diagnosed with a specific type of glioblastoma (MGMT methylated). The main goals are to check safety, find the best dose, and see how the drug behaves in the body. About 36 adults will take part, first in a dose-finding stage and then in a larger group to confirm the chosen dose.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Mayo Clinic Hospital

    Phoenix, Arizona, 85054, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Mayo Clinic Hospital

    Jacksonville, Florida, 32224, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Mayo Clinic Hospital

    Rochester, Minnesota, 55905, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.

Conditions inferred from the trial description

These were inferred from the trial's summary, not listed by the trial registrant.